A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Inclusion Criteria:
Exclusion Criteria:
Sacramento, California 95817, United States
Aurora, Colorado 80045, United States
Englewood, Colorado 80113, United States
Washington D.C., District of Columbia 20037, United States
Washington D.C., District of Columbia 20422, United States
Highland Park, Illinois 60035, United States
Pekin, Illinois 61554, United States
Saint Louis Park, Minnesota 55416, United States
East Orange, New Jersey 07018-1095, United States
Brooklyn, New York 11209, United States
East Syracuse, New York 13057, United States
Winston-Salem, North Carolina 27104, United States
Wpafb, Ohio 45433-5529, United States
Scranton, Pennsylvania 18508, United States
Charleston, South Carolina 29414, United States
Spartanburg, South Carolina 29307, United States
Houston, Texas 77030, United States
Stevens Point, Wisconsin 54481, United States
Sturgeon Bay, Wisconsin 54235-1495, United States
Summit, Wisconsin 53066, United States